Ardena News and Resources

Ardena, a contract development and manufacturing organisation (CDMO) and bioanalytical contract research organisation (CRO), has announced the acquisition of Catalent’s drug product manufacturing facility in Somerset, New Jersey. The move marks a key step in Ardena’s North American expansion, enhancing

Ardena, a pharmaceutical Contract Development and Manufacturing Organisation (CDMO), has announced the full GMP approval of its newly expanded nanomedicine manufacturing facility in Oss. This approval, granted by the Dutch Healthcare Authority, is a significant milestone for the company in

Ardena, a pharmaceutical contract development and manufacturing organisation (CDMO), has announced an expansion of its bioanalytical services in the Netherlands. The investment includes a 3,000-square-foot lab at Pivot Park in Oss, expected to be operational by Q1 2025, alongside upgrades

Ardena announced a significant change in its leadership. Harry Christiaens, who has led the company as CEO for 20 years, is stepping down and will be succeeded by Jeremie Trochu. Christiaens will continue to serve on Ardena’s Board. Trochu is

Ardena, a Contract Development and Manufacturing Organisation (CDMO), has announced the receipt of Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories. This approval is part of the company’s recent expansion of its nanomedicines